

Trust Headquarters  
Russells Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ

Ref: FOI-052025-0001648

Date: 24.6.25

Address / Email:

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000.

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of January 2025 to the end of March 2025, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the

3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	46
1.2 Alpelisib (Piqray)	2
1.3 Elacestrant (Orserdu)	2
1.4 Fulvestrant (fulvestrant or Faslodex)	12
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	37
1.7 Ribociclib (Kisqali)	27
1.8 Capivasertib (Truqap)	0
1.9 Talazoparib (Talzenna)	1
1.10 Olaparib (Lynparza)	11

Q2. How many patients received the following medicines for **early breast cancer** in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	3
2.2 Ribociclib (Kisqali)	0

2.3 Olaparib (Lynparza)	1
-------------------------	---

Q3. How many patients received the following medicines with **curative** treatment intent in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	5
3.2 Ribociclib (Kisqali)	0

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	8
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	3
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	4

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025?

Type of breast cancer	Number patients treated
5.1 All types of breast cancer	1
5.2 Locally advanced or metastatic breast cancer	0

Q6. How many patients were treated in total with the following products in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	2
6.2 Pertuzumab with Trastuzumab (Phesgo)	37
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	28
6.4 Trastuzumab Deruxtecan (EnHertu)	11
6.5 Trastuzumab Emtansine (Kadcyla)	8
6.6 Tucatinib (Tukysa)	0
6.7 Neratinib (Nerlynx)	2

Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (*ICD-10 codes = C50\*, D509*) in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	20
7.2 Trastuzumab Deruxtecan (EnHertu)	11

Q8. How many patients received the following products with **curative treatment intent** in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
8.1 Pertuzumab (Perjeta)	0
8.2 Pertuzumab with Trastuzumab (Phesgo)	1
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	3
8.4 Trastuzumab Emtansine (Kadcyla)	3

Q9. How many patients received the following products as part of **neoadjuvant** or **adjuvant** therapy in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
9.1 Pertuzumab (Perjeta)	0
9.2 Pertuzumab with Trastuzumab (Phesgo)	22
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	15
9.4 Trastuzumab Emtansine (Kadcyla)	3

Q10. How many patients received **trastuzumab deruxtecan (Enhertu)** for the following types of breast cancer in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
10.1 HER2+ <b>ve</b> Breast Cancer	11
10.2 HER2- <b>low</b> Breast Cancer	0

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

FOI/REF FOI-

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team**  
**The Dudley Group NHS Foundation Trust**